{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T03:20:28Z","timestamp":1782876028549,"version":"3.54.5"},"reference-count":36,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2021,1,25]],"date-time":"2021-01-25T00:00:00Z","timestamp":1611532800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Dermatologic Therapy"],"published-print":{"date-parts":[[2021,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Topical treatments are first\u2010line therapies, prescribed to most patients with chronic plaque psoriasis. This non\u2010interventional, longitudinal study examined data regarding the treatment pathways of French patients with psoriasis vulgaris using a pharmacy database. From this database, patients with an initial prescription of a topical treatment of interest (ie, calcipotriol alone and\/or calcipotriol\/betamethasone) between March and October 2013 were included in the study. The primary objective was to capture the switch from a topical treatment, from treatment initiation to receipt of a systemic therapy over a period of 3\u2009years. A total of 26\u2009605 patients were included in the study. The mean age was 58.5\u2009years. The majority of patients (94.7%) maintained topical treatment during the 3\u2009years, receiving a mean of 1.1 different therapies. Of 1400 patients who switched to a systemic therapy, 93.1% switched to a non\u2010biological (mean time to switching &gt;400\u2009days), maintaining this for the remainder of the follow\u2010up period. The most commonly prescribed first non\u2010biological systemic therapy was methotrexate (37%). Less than 1% of patients switched to a biological therapy during follow up. Cohort analyses suggest that patients progressing to use of a systemic therapy within 12\u2009months were those with more severe disease. There was a low rate of transition from topical to systemic therapies in patients with chronic plaque psoriasis during the first 3\u2009years of treatment, suggesting stability of disease severity over time with topical therapy alone, potentially due to good patient adherence.<\/jats:p>","DOI":"10.1111\/dth.14781","type":"journal-article","created":{"date-parts":[[2021,1,17]],"date-time":"2021-01-17T12:14:51Z","timestamp":1610885691000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Topical medications for chronic plaque psoriasis: A 3\u2010year longitudinal study in France"],"prefix":"10.1155","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5780-1827","authenticated-orcid":false,"given":"Emmanuel","family":"Mahe","sequence":"first","affiliation":[{"name":"Department of Dermatology Victor Dupouy Hospital  Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah\u2010Hind","family":"Moumane","sequence":"additional","affiliation":[{"name":"Medical Department LEO Pharma  Voisins\u2010Le\u2010Bretonneux France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Murielle","family":"Foist","sequence":"additional","affiliation":[{"name":"Medical Department LEO Pharma  Voisins\u2010Le\u2010Bretonneux France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2021,1,25]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.2165\/11591580-000000000-00000"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1586\/14737167.2014.914437"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1590\/abd1806-4841.20154147"},{"issue":"2","key":"e_1_2_9_5_1","first-page":"34","article-title":"Fixed combination aerosol foam calcipotriene 0.005% (Cal) plus betamethasone dipropionate 0.064% (BD) is more efficacious than Cal or BD aerosol foam alone for psoriasis vulgaris: a randomized, double\u2010blind, multicenter, three\u2010arm, phase 2 study","volume":"9","author":"Lebwohl M","year":"2016","journal-title":"J Clin Aesthet Dermatol"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2012.339"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.14959"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2008.12.032"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2010.11.055"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00403-010-1080-1"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.15665"},{"issue":"6","key":"e_1_2_9_12_1","first-page":"609","article-title":"Consensus on the use of the fixed combination calcipotriol\/betamethasone dipropionate in the treatment of plaque psoriasis","volume":"147","author":"Girolomoni G","year":"2012","journal-title":"G Ital Dermatol Venereol"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.12058"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.13354"},{"key":"e_1_2_9_15_1","unstructured":"National Institute for Health and Care Excellence.Guselkumab for treating moderate to severe plaque psoriasis.2018.https:\/\/www.nice.org.uk\/guidance\/ta521. Accessed October 8 2018."},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-018-0698-2"},{"issue":"6","key":"e_1_2_9_17_1","first-page":"699","article-title":"Factors affecting prescription of ultra\u2010high potency topical corticosteroids in skin disease: an analysis of US national practice data","volume":"4","author":"Balkrishnan R","year":"2005","journal-title":"J Drugs Dermatol"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1368-5031.2005.00680.x"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2012.10991.x"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdermsci.2016.08.535"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-016-0153-2"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2016.1255304"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/dth.12567"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1159\/000366499"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.13747"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1159\/000491782"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.15340"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2009.03.027"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.14406"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2005.12.021"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2013.5264"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2013.12.018"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1002\/psb.1517"},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.12372"},{"key":"e_1_2_9_35_1","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-2625"},{"key":"e_1_2_9_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2012.07.007"},{"key":"e_1_2_9_37_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00403-013-1372-3"}],"container-title":["Dermatologic Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/dth.14781","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/dth.14781","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/dth.14781","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T14:59:06Z","timestamp":1764169146000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/dth.14781"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,25]]},"references-count":36,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["10.1111\/dth.14781"],"URL":"https:\/\/doi.org\/10.1111\/dth.14781","archive":["Portico"],"relation":{},"ISSN":["1396-0296"],"issn-type":[{"value":"1396-0296","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1,25]]},"assertion":[{"value":"2020-09-28","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-12-21","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-01-25","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e14781"}}